BN Against Cancer

  • Author: David Bradley
  • Published: 23 June 2013
  • Copyright: WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: Chemical Communications/RSC
thumbnail image: BN Against Cancer

Dmitri Golberg of the National Institute for Materials Science in Tsukuba, Japan, and colleagues have demonstrated how functionalizing boron nitride (BN) nanotubes with mesoporous silica allows them to carry out intracellular delivery of chemotherapy agents.

The team has demonstrated proof of principle by loading up their BN@silica hybrids with the well-established anticancer drug, doxorubicin, commonly used in leukemia and lymphoma. The use of a nanotube host should allow much better targeting with such agents, which can have serious side effects. In the case of doxorubicin, life-threatening damage to the heart tissue can occur.

The team has shown that their hybrid improves the effectiveness of the drug in killing LNcap prostate cancer cells compared with unloaded nanotubes as controls.

Article Views: 3952

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from, please contact us first for permission. more

CONNECT: on Facebook on Twitter on YouTube on LinkedIn Sign up for our free newsletter

Magazine of Chemistry Europe (16 European Chemical Societies)published by Wiley-VCH